Literature DB >> 23642732

Association of SNPs in the UGT1A gene cluster with total bilirubin and mortality in the Diabetes Heart Study.

Amanda J Cox1, Maggie C-Y Ng, Jianzhao Xu, Carl D Langefeld, Kenneth L Koch, Paul A Dawson, J Jeffrey Carr, Barry I Freedman, Fang-Chi Hsu, Donald W Bowden.   

Abstract

OBJECTIVE: A negative relationship between total bilirubin concentration (TBili) and CVD risk has been documented in a series of epidemiological studies. In addition, TBili is thought to be under strong genetic regulation via the UGT1A gene family, suggesting it may be a heritable CVD risk factor. However, few studies directly relate TBili-associated UGT1A variants to CVD severity or outcome. This study replicated the genetic association for TBili in the Diabetes Heart Study (DHS), and examined the relationships of TBili-associated SNPs with measures of subclinical CVD and mortality.
METHODS: This investigation included 1220 self-described European American (EA) individuals from the DHS, a family-based study examining risk for macrovascular complications in type 2 diabetes (T2D). Genetic associations with TBili were examined using the Affymetrix Genome-wide Human SNP Array 5.0 and the Illumina Infinium Human Exome beadchip v1.0. Subsequent analyses assessed the relationships of the top TBili-associated SNPs with measures of vascular calcified plaque and mortality.
RESULTS: A genome-wide association study detected 18 SNPs within the UGT1A gene family associated with TBili at p < 5 × 10(-8). The top hit was rs887829 (p = 8.67 × 10(-20)). There was no compelling evidence of association between the top TBili-associated SNPs and vascular calcified plaque (p = 0.05-0.88). There was, however, evidence of association with all-cause mortality (p = 0.0004-0.06), the top hit being rs2741034.
CONCLUSION: These findings support a potential role for UGT1A genetic variants in risk for mortality in T2D. Further quantification of the extent of CVD risk conferred by UGT1A gene family variants in a high risk cohort with T2D is still required.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23642732      PMCID: PMC3691283          DOI: 10.1016/j.atherosclerosis.2013.04.008

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  28 in total

1.  UGT1A1*28 allele and coronary heart disease: the Rotterdam Study.

Authors:  Piter J Bosma; Irene M van der Meer; Conny T Bakker; Albert Hofman; Marianne Paul-Abrahamse; Jacqueline C Witteman
Journal:  Clin Chem       Date:  2003-07       Impact factor: 8.327

2.  Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study.

Authors:  J Jeffrey Carr; Jennifer Clark Nelson; Nathan D Wong; Michael McNitt-Gray; Yadon Arad; David R Jacobs; Stephan Sidney; Diane E Bild; O Dale Williams; Robert C Detrano
Journal:  Radiology       Date:  2005-01       Impact factor: 11.105

3.  Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels.

Authors:  Libor Vítek; Milan Jirsa; Marie Brodanová; Milan Kalab; Zdenek Marecek; Vilém Danzig; Ladislav Novotný; Petr Kotal
Journal:  Atherosclerosis       Date:  2002-02       Impact factor: 5.162

4.  C-reactive protein concentration predicts mortality in type 2 diabetes: the Diabetes Heart Study.

Authors:  A J Cox; S Agarwal; D M Herrington; J J Carr; B I Freedman; D W Bowden
Journal:  Diabet Med       Date:  2012-06       Impact factor: 4.359

5.  Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels.

Authors:  Suzette J Bielinski; High Seng Chai; Jyotishman Pathak; Jayant A Talwalkar; Paul J Limburg; Rachel E Gullerud; Hugues Sicotte; Eric W Klee; Jason L Ross; Jean-Pierre A Kocher; Iftikhar J Kullo; John A Heit; Gloria M Petersen; Mariza de Andrade; Christopher G Chute
Journal:  Mayo Clin Proc       Date:  2011-06-06       Impact factor: 7.616

6.  Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference.

Authors:  Patrick F McArdle; Brian W Whitcomb; Keith Tanner; Braxton D Mitchell; Alan R Shuldiner; Afshin Parsa
Journal:  BMC Cardiovasc Disord       Date:  2012-03-14       Impact factor: 2.298

7.  Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  K H Chan; R L O'Connell; D R Sullivan; L S Hoffmann; K Rajamani; M Whiting; M W Donoghoe; M Vanhala; A Hamer; B Yu; R Stocker; M K C Ng; A C Keech
Journal:  Diabetologia       Date:  2013-01-17       Impact factor: 10.122

8.  Low serum bilirubin concentration is associated with coronary artery calcification (CAC).

Authors:  Muhei Tanaka; Michiaki Fukui; Ki-ichiro Tomiyasu; Satoshi Akabame; Koji Nakano; Goji Hasegawa; Yohei Oda; Naoto Nakamura
Journal:  Atherosclerosis       Date:  2009-02-20       Impact factor: 5.162

9.  Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III.

Authors:  C Mary Schooling; Elizabeth A Kelvin; Heidi E Jones
Journal:  Ann Epidemiol       Date:  2012-09-03       Impact factor: 3.797

10.  The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases.

Authors:  Libor Vítek
Journal:  Front Pharmacol       Date:  2012-04-03       Impact factor: 5.810

View more
  11 in total

1.  Genetic analysis of advanced glycation end products in the DHS MIND study.

Authors:  Jeremy N Adams; Laura M Raffield; Susan E Martelle; Barry I Freedman; Carl D Langefeld; J Jeffrey Carr; Amanda J Cox; Donald W Bowden
Journal:  Gene       Date:  2016-02-23       Impact factor: 3.688

2.  Mendelian randomization analyses support causal relationships between blood metabolites and the gut microbiome.

Authors:  Xiaomin Liu; Xin Tong; Yuanqiang Zou; Xiaoqian Lin; Hui Zhao; Liu Tian; Zhuye Jie; Qi Wang; Zhe Zhang; Haorong Lu; Liang Xiao; Xuemei Qiu; Jin Zi; Rong Wang; Xun Xu; Huanming Yang; Jian Wang; Yang Zong; Weibin Liu; Yong Hou; Shida Zhu; Huijue Jia; Tao Zhang
Journal:  Nat Genet       Date:  2022-01-03       Impact factor: 41.307

3.  Genome-wide analysis of hepatic lipid content in extreme obesity.

Authors:  Johanna K DiStefano; Christopher Kingsley; G Craig Wood; Xin Chu; George Argyropoulos; Christopher D Still; Stefania Cotta Doné; Christophe Legendre; Waibhav Tembe; Glenn S Gerhard
Journal:  Acta Diabetol       Date:  2014-09-23       Impact factor: 4.280

4.  Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.

Authors:  Carrie B Moore; Anurag Verma; Sarah Pendergrass; Shefali S Verma; Daniel H Johnson; Eric S Daar; Roy M Gulick; Richard Haubrich; Gregory K Robbins; Marylyn D Ritchie; David W Haas
Journal:  Open Forum Infect Dis       Date:  2015-01-09       Impact factor: 3.835

5.  Serum bilirubin concentration is modified by UGT1A1 haplotypes and influences risk of type-2 diabetes in the Norfolk Island genetic isolate.

Authors:  M C Benton; R A Lea; D Macartney-Coxson; C Bellis; M A Carless; J E Curran; M Hanna; D Eccles; G K Chambers; J Blangero; L R Griffiths
Journal:  BMC Genet       Date:  2015-12-02       Impact factor: 2.797

6.  A Phenomic Scan of the Norfolk Island Genetic Isolate Identifies a Major Pleiotropic Effect Locus Associated with Metabolic and Renal Disorder Markers.

Authors:  Miles C Benton; Rodney A Lea; Donia Macartney-Coxson; Michelle Hanna; David A Eccles; Melanie A Carless; Geoffrey K Chambers; Claire Bellis; Harald H Goring; Joanne E Curran; Jacquie L Harper; Gregory Gibson; John Blangero; Lyn R Griffiths
Journal:  PLoS Genet       Date:  2015-10-16       Impact factor: 5.917

7.  Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seq.

Authors:  Ana Rubin; Anna C Salzberg; Yuka Imamura; Anzor Grivitishvilli; Joyce Tombran-Tink
Journal:  BMC Genomics       Date:  2016-11-17       Impact factor: 3.969

8.  Rare variants in drug target genes contributing to complex diseases, phenome-wide.

Authors:  Shefali Setia Verma; Navya Josyula; Anurag Verma; Xinyuan Zhang; Yogasudha Veturi; Frederick E Dewey; Dustin N Hartzel; Daniel R Lavage; Joe Leader; Marylyn D Ritchie; Sarah A Pendergrass
Journal:  Sci Rep       Date:  2018-03-15       Impact factor: 4.379

9.  The relationship between total bilirubin levels and total mortality in older adults: the United States National Health and Nutrition Examination Survey (NHANES) 1999-2004.

Authors:  Kwok-Leung Ong; Matthew A Allison; Bernard M Y Cheung; Ben J Wu; Philip J Barter; Kerry-Anne Rye
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

10.  Analysis of common and coding variants with cardiovascular disease in the Diabetes Heart Study.

Authors:  Jeremy N Adams; Laura M Raffield; Barry I Freedman; Carl D Langefeld; Maggie C Y Ng; J Jeffrey Carr; Amanda J Cox; Donald W Bowden
Journal:  Cardiovasc Diabetol       Date:  2014-04-12       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.